🔴 LifeMD is trading 10.33% down today after Q2 revenue miss and lowered full-year guidance

LifeMD is trading at $3.27 (10.33% down) after the company reported second-quarter revenue that missed analyst estimates and lowered its full-year 2026 guidance.

• The company reported Q2 revenue of $47.3 million and a loss of $0.16 per share.
• Management stated that a strategic shift toward branded GLP-1 therapies is currently pressuring near-term profitability.